Teaching General Hospital "Martín Chang Puga", Nuevitas, Camagüey, Cuba.
Communitarian Teaching Policlinic "Mario Muñoz Monroy", Vertientes, Camagüey, Cuba.
Afr Health Sci. 2023 Jun;23(2):43-55. doi: 10.4314/ahs.v23i2.6.
Effective and safe antiviral treatments are required to refrain the COVID-19.
Investigate the efficacy and safety of interferon in the treatment of COVID-19.
The inclusion criteria were patients who gave their signed consent, with detection confirmed by RT-PCR of SARS-CoV-2, 18 years and older. Patients received therapy as per the Guinea COVID-19 protocol in the group B; the group A received the same treatment including administration of interferon. The outcome measures the time to negative conversion of SARS-CoV-2, mortality, patients transferred to ICU and safety, according to the reports of adverse events.
345 patients were included, 171 in the group A and 174 in the group B. After the treatments, the RT-PCR negative results were attained in the patients in the group A in 9.15±4.79 days and in those in the group B in 14.83±6.67 days. No patient in the group A had to be transferred to ICU, and they all survived; in the group B, 26 patients were transferred to ICU and six of them died. There were eight adverse events with causality relation with interferon administration.
The interferon resulted effective and safe in contributing to the viral replication conversion to negative results in shorter time and to survival.
需要有效的和安全的抗病毒治疗来遏制 COVID-19。
研究干扰素治疗 COVID-19 的疗效和安全性。
纳入标准为签署知情同意书的患者，通过 SARS-CoV-2 的 RT-PCR 检测确认，年龄在 18 岁及以上。患者根据几内亚 COVID-19 方案在 B 组接受治疗；A 组接受相同的治疗，包括干扰素的给药。根据不良事件报告，主要结局是 SARS-CoV-2 阴转时间、死亡率、转 ICU 患者和安全性。
共纳入 345 例患者，A 组 171 例，B 组 174 例。治疗后，A 组患者的 RT-PCR 阴性结果出现在第 9.15±4.79 天，B 组出现在第 14.83±6.67 天。A 组无患者需要转 ICU，且全部存活；B 组有 26 例患者转 ICU，其中 6 例死亡。有 8 例不良事件与干扰素给药有关。
干扰素在促进病毒复制向阴性结果转化和提高生存率方面有效且安全，作用时间更短。
